Click Therapeutics

Click Therapeutics, Inc. specializes in the development and commercialization of digital therapeutics aimed at addressing unmet medical needs through cognitive and neurobehavioral modification. Founded in 2012 and based in New York, the company designs software as medical treatments for various conditions, including smoking cessation, major depressive disorders, schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Their innovative Digital Therapeutics™ are intended for standalone use or in conjunction with traditional biomedical treatments, enhancing patient outcomes through personalized experiences driven by the Clickometrics® adaptive data science platform. Notably, Click's smoking cessation program has gained nationwide availability through multiple payers, providers, and employers, while their leading prescription program is currently undergoing a phase III clinical trial for Major Depressive Disorder in adults.